Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

mefanamic acid 250mg

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

mefenanic acid 250mg

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

chloramphenicol 1.0g

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

chloramphenicol 250mg

Philippines - English - FDA (Food And Drug Administration)

rl pharma distributor - mefenamic acid - capsule - 500mg

Pakistan - English - Zafa Pharmaceutical

zafa pharmaceutical - tablets - mefenamic acid 250mg - anti-inflammatory / n.s.a.i.d

Pakistan - English - Zafa Pharmaceutical

zafa pharmaceutical - tablets - mefenamic acid 250mg - anti-inflammatory / n.s.a.i.d

Israel - English - Ministry of Health

novartis israel ltd - fingolimod as hydrochloride - hard capsule - fingolimod as hydrochloride 0.5 mg - fingolimod - fingolimod - gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( ms ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - fingolimod hydrochloride 0.56mg;  ;  ;   - capsule - 0.5 mg - active: fingolimod hydrochloride 0.56mg       excipient: capsugel white 4998 gelatin ink iron oxide yellow magnesium stearate mannitol titanium dioxide - gilenya is indicated as a disease modifying therapy for the treatment of patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: mannitol; iron oxide yellow; magnesium stearate; gelatin; titanium dioxide - fingolimod sandoz is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.